Literature DB >> 22627184

Undiagnosed tuberculosis among HIV clinic attendees: association with antiretroviral therapy and implications for intensified case finding, isoniazid preventive therapy, and infection control.

Tendesayi Kufa1, Victor Mngomezulu, Salome Charalambous, Yasmeen Hanifa, Katherine Fielding, Alison D Grant, Nikolas Wada, Richard E Chaisson, Gavin J Churchyard, Celine R Gounder.   

Abstract

OBJECTIVES: Initiation of antiretroviral therapy (ART) and the 3I's are strategies to prevent HIV-associated tuberculosis (TB). We describe factors associated with undiagnosed TB among HIV-infected patients attending an HIV clinic in South Africa and discuss implications for the 3 Is.
DESIGN: Convenience sample of HIV clinic attendees.
METHODS: HIV-infected participants were assessed for TB using a symptom screen, sputum-smear microscopy, sputum and blood mycobacterial culture, fine needle aspiration of enlarged lymph nodes, and chest radiography.
RESULTS: Four hundred twenty-two participants were enrolled. The median age and CD4+ T-cell count were 37 years [interquartile range (IQR): 31-44 years] and 215 cells per microliter (IQR: 107-347 cells/μL). Forty-seven percent had been on ART for a median duration of 8 months (IQR: 3.3-22.8 months). Three hundred sixty-one participants (85.6%) reported TB symptoms. Twenty-seven participants (6.4%) met criteria for bacteriologically confirmed TB and 50 (11.6%) for any form of TB. Bacteriologically confirmed TB was associated with CD4+ T-cell counts ≤100 cells per microliter (odds ratio: 5.05, 95% confidence interval: 1.69 to 15.12) when compared with CD4+ T-cell counts >200 cells per microliter and hemoglobin {hemoglobin < 10 g/dL [odds ratio 3.12 (95% confidence interval: 1.26 to 7.72)]}.
CONCLUSIONS: Undiagnosed TB among HIV-infected ambulatory patients was associated with low CD4+ T-cell counts regardless of ART status. TB screening algorithms which include CD4+ T-cell count and hemoglobin testing may be an effective way to identify HIV-infected clinic attendees at highest risk of undiagnosed TB. Isoniazid preventive therapy and TB infection control are essential for reducing occurrence of HIV-associated TB even after ART initiation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22627184     DOI: 10.1097/QAI.0b013e318251ae0b

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  26 in total

1.  Performance of symptom-based tuberculosis screening among people living with HIV: not as great as hoped.

Authors:  Faiz Ahmad Khan; Sabine Verkuijl; Andrew Parrish; Fadzai Chikwava; Raphael Ntumy; Wafaa El-Sadr; Andrea A Howard
Journal:  AIDS       Date:  2014-06-19       Impact factor: 4.177

2.  C-reactive protein and tuberculosis screening: a new trick for an old dog?

Authors:  Christina Yoon; J Lucian Davis; Adithya Cattamanchi
Journal:  Int J Tuberc Lung Dis       Date:  2013-12       Impact factor: 2.373

3.  Yield and Efficiency of Novel Intensified Tuberculosis Case-Finding Algorithms for People Living with HIV.

Authors:  Christina Yoon; Fred C Semitala; Lucy Asege; Jane Katende; Sandra Mwebe; Alfred O Andama; Elly Atuhumuza; Martha Nakaye; Derek T Armstrong; David W Dowdy; Charles E McCulloch; Moses Kamya; Adithya Cattamanchi
Journal:  Am J Respir Crit Care Med       Date:  2019-03-01       Impact factor: 21.405

Review 4.  Diagnostic accuracy of C-reactive protein for active pulmonary tuberculosis: a meta-analysis.

Authors:  C Yoon; L H Chaisson; S M Patel; I E Allen; P K Drain; D Wilson; A Cattamanchi
Journal:  Int J Tuberc Lung Dis       Date:  2017-09-01       Impact factor: 2.373

Review 5.  Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection.

Authors:  Paul K Drain; Kristina L Bajema; David Dowdy; Keertan Dheda; Kogieleum Naidoo; Samuel G Schumacher; Shuyi Ma; Erin Meermeier; David M Lewinsohn; David R Sherman
Journal:  Clin Microbiol Rev       Date:  2018-07-18       Impact factor: 26.132

6.  Optimizing the protection of research participants and personnel in HIV-related research where TB is prevalent: practical solutions for improving infection control.

Authors:  Jason E Farley; Timothy F Landers; Catherine Godfrey; Virginia Lipke; Jeremy Sugarman
Journal:  J Acquir Immune Defic Syndr       Date:  2014-01-01       Impact factor: 3.731

Review 7.  Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality.

Authors:  E L Corbett; P MacPherson
Journal:  Int J Tuberc Lung Dis       Date:  2013-09       Impact factor: 2.373

8.  Point-of-care C-reactive protein testing to facilitate implementation of isoniazid preventive therapy for people living with HIV.

Authors:  Christina Yoon; J Lucian Davis; Laurence Huang; Conrad Muzoora; Helen Byakwaga; Colin Scibetta; David R Bangsberg; Payam Nahid; Fred C Semitala; Peter W Hunt; Jeffrey N Martin; Adithya Cattamanchi
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-15       Impact factor: 3.731

9.  Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis.

Authors:  Harriet L Mills; Ted Cohen; Caroline Colijn
Journal:  Sci Transl Med       Date:  2013-04-10       Impact factor: 17.956

10.  Effect of antiretroviral therapy on the diagnostic accuracy of symptom screening for intensified tuberculosis case finding in a South African HIV clinic.

Authors:  Molebogeng X Rangaka; Robert J Wilkinson; Judith R Glynn; Andrew Boulle; Gilles van Cutsem; Rene Goliath; Shaheed Mathee; Gary Maartens
Journal:  Clin Infect Dis       Date:  2012-09-05       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.